Загрузка...

Bevacizumab-induced nasal septal perforation: Incidence of symptomatic, confirmed event(s) in colorectal cancer patients

PURPOSE: In breast cancer patients, Mailliez and others described that 5 of 70 patients (7%) developed a bevacizumab-induced nasal septal perforation. However, to date, no studies have reported such rates in colorectal cancer patients, who derive a survival advantage with this drug. METHODS: This st...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Acta Oncol
Главные авторы: Ramiscal, Judi Anne B., Jatoi, Aminah
Формат: Artigo
Язык:Inglês
Опубликовано: 2010
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6014966/
https://ncbi.nlm.nih.gov/pubmed/21108568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/0284186X.2010.537692
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!